Market Overview

Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure

Share:

Ology Bioservices, Inc., a biologics contract development and
manufacturing organization (CDMO), announced today that it was awarded
an Other Transaction Agreement (OTA) to support the Joint Project
Manager Medical Countermeasure Systems (JPM-MCS), a component of the
Joint Program Executive Office for Chemical, Biological, Radiological
and Nuclear Defense (JPEO CBRND) for advanced biologics manufacturing
services—specifically, to manufacture an anti-Ebola monoclonal antibody
(mAb). The award was made possible through collaborative funding between
JPEO CBRND and the Defense Advanced Research Projects Agency (DARPA).
The antibody, designated mAb114, was developed at the Vaccine Research
Center (VRC), part of the National Institute of Allergy and Infectious
Diseases (NIAID) with the National Institutes of Health, in part through
funding previously provided by DARPA. The VRC is a collaborator with
JPM-MCS, DARPA, and Ology Bioservices on this program. Including
optional work, the agreement has a value of $8.4 million.

Ebola is a rare and deadly disease endemic to Africa; it has been
identified as a potential biothreat agent by the U.S. Department of
Defense (DoD). Under terms of the contract, Ology Bioservices will
perform technology transfer of the Ebola mAbs production process into
the Department of Defense Advanced Development Manufacturing Facility
(DoD ADM). The DoD ADM Facility is a 183,000-square foot,
state-of-the-art, multi-purpose, multi-product, Biosafety Level
3-capable facility operated by the company in Alachua, Florida. The
product will be produced using cGMP manufacturing at a volume of 500 L
and is expected to be delivered in December 2018. The agreement includes
an option for two additional manufacturing lots to be delivered in early
2019.

"Given the inherent danger posed by Ebola to the global population,
there is an urgent need to mitigate future outbreaks by ensuring rapid
and efficient manufacturing and delivery of a protective countermeasure.
Based on our successful work with other important biologics
countermeasures, we are pleased to have been selected by the DoD to
provide this critical product," stated Peter H. Khoury, Ph.D., MBA,
President and Chief Executive Officer of Ology Bioservices.

About Ebola Virus Disease

The Ebola virus was first discovered in 1976 near the Ebola River in
what is now the Democratic Republic of Congo. It is a rare and deadly
disease in both people and nonhuman primates (monkeys, gorillas, and
chimpanzees). Scientists believe that people are initially infected with
Ebola through contact with an infected animal. Once in humans, the virus
spreads through direct contact with bodily fluids of a person who is
sick with, or, has died from Ebola.

The highly publicized 2014-2016 Ebola outbreak in West Africa began in a
rural setting of southeastern Guinea, spread to urban areas and across
borders within weeks, and became a global epidemic within months,
killing more than 11,000 people in West Africa, alone. Most recently, on
May 8, 2018, the Democratic
Republic of Congo
's health minister declared another Ebola outbreak.

Current treatment of patients with suspected or confirmed Ebola
infection includes quarantine, symptom management, and supportive care,
since there are no approved vaccines or treatments yet available for
human use. Meanwhile, studies of patients treated with convalescent
plasma and monoclonal antibodies have yielded encouraging results.

About Ology Bioservices

Ology Bioservices is a full-service Contract Development Manufacturing
Organization (CDMO) serving both government and commercial clients,
specializing in biologic drug substance manufacturing, from early stage
through commercial product. The company has 183,000 square feet of
manufacturing, process development and QA/QC space in its
state-of-the-art, Department of Defense Advanced Development and
Manufacturing Facility in Florida. The company's infrastructure provides
unique services to its clients, including full regulatory support from
preclinical through licensure, clinical trial operational support and
bioanalytical testing, as well as cGMP manufacturing up to Biosafety
Level 3 (BSL3). Ology Bioservices has 20 years of experience developing
and manufacturing drugs and biologics for the U.S. Government, with over
$500M in government contracts awarded over that time. The team at Ology
Bioservices has decades of experience manufacturing, developing and
licensing vaccines and protein/antibody therapeutics.

View Comments and Join the Discussion!